Cargando…

High prevalence of secondary bladder cancer in men on radiotherapy for prostate cancer: evidence from a meta-analysis

OBJECTIVE: To assess whether radiotherapy (RT) for prostate cancer (PCa) was a risk factor for secondary bladder cancer (BLCa) through a meta-analysis. MATERIALS AND METHODS: The MEDLINE, Embase, and the Cochrane Library were systematically searched for all studies investigating the risk of BLCa in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Shankun, Xie, Qiang, Yang, Redian, Wang, Jiamin, Zhang, Chaofeng, Luo, Lianmin, Zhu, Zhiguo, Liu, Yangzhou, Li, Ermao, Zhao, Zhigang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331076/
https://www.ncbi.nlm.nih.gov/pubmed/30666156
http://dx.doi.org/10.2147/CMAR.S185867
_version_ 1783387082808360960
author Zhao, Shankun
Xie, Qiang
Yang, Redian
Wang, Jiamin
Zhang, Chaofeng
Luo, Lianmin
Zhu, Zhiguo
Liu, Yangzhou
Li, Ermao
Zhao, Zhigang
author_facet Zhao, Shankun
Xie, Qiang
Yang, Redian
Wang, Jiamin
Zhang, Chaofeng
Luo, Lianmin
Zhu, Zhiguo
Liu, Yangzhou
Li, Ermao
Zhao, Zhigang
author_sort Zhao, Shankun
collection PubMed
description OBJECTIVE: To assess whether radiotherapy (RT) for prostate cancer (PCa) was a risk factor for secondary bladder cancer (BLCa) through a meta-analysis. MATERIALS AND METHODS: The MEDLINE, Embase, and the Cochrane Library were systematically searched for all studies investigating the risk of BLCa in patients with RT. The association between RT and risk of BLCa was summarized using hazard ratio with a 95%CI. The protocol for this meta-analysis is available from PROSPERO (CRD42018090075). RESULTS: Overall, 619,479 participants (age: 57–79 years) were included from 15 studies, 206,852 of whom were patients who received RT. Synthesis of results indicated that RT was significantly associated with an increased risk of BLCa compared with the risk in those who received radical prostatectomy or non-RT (overall HR=1.6, 95%CI: 1.33–1.92, P<0.001). The results were consistent when restricted to a 5-year lag period (HR=1.84, 95%CI: 1.26–2.69, P=0.002) and multivariable adjustment (HR=1.96, 95%CI: 1.47–2.62, P<0.001), but not for 10-year lag period (HR=1.93, 95%CI: 0.9– 4.16, P=0.093) and brachytherapy subgroup (HR=1.33, 95%CI: 0.87–2.05, P=0.188). The GRADE-profiler revealed that the rate of events of BLCa on average in the RT-patients and the non-RT control was 2,462/183,669 (1.3%) and 4,263/382,761(1.1%), respectively; the overall quality of the evidence was low. CONCLUSION: Patients who received RT for PCa was associated with higher risks of developing secondary BLCa compared to those unexposed to RT, but the absolute effect was low.
format Online
Article
Text
id pubmed-6331076
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-63310762019-01-21 High prevalence of secondary bladder cancer in men on radiotherapy for prostate cancer: evidence from a meta-analysis Zhao, Shankun Xie, Qiang Yang, Redian Wang, Jiamin Zhang, Chaofeng Luo, Lianmin Zhu, Zhiguo Liu, Yangzhou Li, Ermao Zhao, Zhigang Cancer Manag Res Review OBJECTIVE: To assess whether radiotherapy (RT) for prostate cancer (PCa) was a risk factor for secondary bladder cancer (BLCa) through a meta-analysis. MATERIALS AND METHODS: The MEDLINE, Embase, and the Cochrane Library were systematically searched for all studies investigating the risk of BLCa in patients with RT. The association between RT and risk of BLCa was summarized using hazard ratio with a 95%CI. The protocol for this meta-analysis is available from PROSPERO (CRD42018090075). RESULTS: Overall, 619,479 participants (age: 57–79 years) were included from 15 studies, 206,852 of whom were patients who received RT. Synthesis of results indicated that RT was significantly associated with an increased risk of BLCa compared with the risk in those who received radical prostatectomy or non-RT (overall HR=1.6, 95%CI: 1.33–1.92, P<0.001). The results were consistent when restricted to a 5-year lag period (HR=1.84, 95%CI: 1.26–2.69, P=0.002) and multivariable adjustment (HR=1.96, 95%CI: 1.47–2.62, P<0.001), but not for 10-year lag period (HR=1.93, 95%CI: 0.9– 4.16, P=0.093) and brachytherapy subgroup (HR=1.33, 95%CI: 0.87–2.05, P=0.188). The GRADE-profiler revealed that the rate of events of BLCa on average in the RT-patients and the non-RT control was 2,462/183,669 (1.3%) and 4,263/382,761(1.1%), respectively; the overall quality of the evidence was low. CONCLUSION: Patients who received RT for PCa was associated with higher risks of developing secondary BLCa compared to those unexposed to RT, but the absolute effect was low. Dove Medical Press 2019-01-10 /pmc/articles/PMC6331076/ /pubmed/30666156 http://dx.doi.org/10.2147/CMAR.S185867 Text en © 2019 Zhao et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Zhao, Shankun
Xie, Qiang
Yang, Redian
Wang, Jiamin
Zhang, Chaofeng
Luo, Lianmin
Zhu, Zhiguo
Liu, Yangzhou
Li, Ermao
Zhao, Zhigang
High prevalence of secondary bladder cancer in men on radiotherapy for prostate cancer: evidence from a meta-analysis
title High prevalence of secondary bladder cancer in men on radiotherapy for prostate cancer: evidence from a meta-analysis
title_full High prevalence of secondary bladder cancer in men on radiotherapy for prostate cancer: evidence from a meta-analysis
title_fullStr High prevalence of secondary bladder cancer in men on radiotherapy for prostate cancer: evidence from a meta-analysis
title_full_unstemmed High prevalence of secondary bladder cancer in men on radiotherapy for prostate cancer: evidence from a meta-analysis
title_short High prevalence of secondary bladder cancer in men on radiotherapy for prostate cancer: evidence from a meta-analysis
title_sort high prevalence of secondary bladder cancer in men on radiotherapy for prostate cancer: evidence from a meta-analysis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331076/
https://www.ncbi.nlm.nih.gov/pubmed/30666156
http://dx.doi.org/10.2147/CMAR.S185867
work_keys_str_mv AT zhaoshankun highprevalenceofsecondarybladdercancerinmenonradiotherapyforprostatecancerevidencefromametaanalysis
AT xieqiang highprevalenceofsecondarybladdercancerinmenonradiotherapyforprostatecancerevidencefromametaanalysis
AT yangredian highprevalenceofsecondarybladdercancerinmenonradiotherapyforprostatecancerevidencefromametaanalysis
AT wangjiamin highprevalenceofsecondarybladdercancerinmenonradiotherapyforprostatecancerevidencefromametaanalysis
AT zhangchaofeng highprevalenceofsecondarybladdercancerinmenonradiotherapyforprostatecancerevidencefromametaanalysis
AT luolianmin highprevalenceofsecondarybladdercancerinmenonradiotherapyforprostatecancerevidencefromametaanalysis
AT zhuzhiguo highprevalenceofsecondarybladdercancerinmenonradiotherapyforprostatecancerevidencefromametaanalysis
AT liuyangzhou highprevalenceofsecondarybladdercancerinmenonradiotherapyforprostatecancerevidencefromametaanalysis
AT liermao highprevalenceofsecondarybladdercancerinmenonradiotherapyforprostatecancerevidencefromametaanalysis
AT zhaozhigang highprevalenceofsecondarybladdercancerinmenonradiotherapyforprostatecancerevidencefromametaanalysis